NCT04366531 Successful Transitions and Reintegration Tools for Veterans (START-VETS)
| NCT ID | NCT04366531 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Substance Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2020-08-03 |
| Primary Completion | 2026-10-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2020-08-03 with a primary completion date of 2026-10-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will develop prison reentry materials for Veterans leaving prison.
Eligibility Criteria
Inclusion Criteria: * Veteran with mental illness and/or substance use disorder released from prison within the past 36 months Exclusion Criteria: * psychosis or cognitive impairment precluding active participation
Contact & Investigator
James P. LePage, PhD
PRINCIPAL INVESTIGATOR
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Frequently Asked Questions
Who can join the NCT04366531 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Substance Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04366531 currently recruiting?
Yes, NCT04366531 is actively recruiting participants. Contact the research team at april.crawford@va.gov for enrollment information.
Where is the NCT04366531 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT04366531 clinical trial?
NCT04366531 is sponsored by VA Office of Research and Development. The principal investigator is James P. LePage, PhD at VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX. The trial plans to enroll 20 participants.